Catenacci, Daniel V T <br/><br/>
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  11 2017 
 - 1467-1482 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(17)30566-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Capecitabine--administration & dosage<br/>Cisplatin--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Epirubicin--administration & dosage<br/>Esophageal Neoplasms--drug therapy<br/>Esophagogastric Junction--pathology<br/>Humans<br/>Internationality<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Prognosis<br/>Proportional Hazards Models<br/>Proto-Oncogene Proteins c-met--drug effects<br/>Stomach Neoplasms--drug therapy<br/>Survival Analysis<br/>Treatment Outcome